January 5, 2024 11:06 AM ESTUpdated 01:19 PM
Deals
R&D

Mer­ck CEO in­di­cates in­ter­est in GLP-1 com­bi­na­tion ther­a­pies, may pur­sue deals

Max Gelman

Senior Editor

Not want­i­ng to be left out in the cold, Mer­ck now plans to pur­sue GLP-1 com­bi­na­tion ther­a­pies amid grow­ing ex­cite­ment about the lu­cra­tive po­ten­tial of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times